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Abstract
Preclinical studies have shown that peroxisome proliferator–activated receptor γ (PPAR-γ) ligands can exert antitumor
effects against non–small cell lung cancer (NSCLC) and a variety of other cancers. In this study, we investigate the
potential use of a PPAR-γ ligand, troglitazone (Tro), in combination with either of two chemotherapeutic agents, cis-
platin (Cis) or paclitaxel (Pac), for the treatment of NSCLC. In vitro, treatment of NSCLC cell lines with Tro potentiated
Cis- or Pac-induced growth inhibition. The potentiation of growth inhibition was observed only when Cis or Pac treat-
ment was followed by Tro and not vice versa, demonstrating a sequence-specific effect. Median effect analysis
revealed a synergistic interaction between Tro and Cis in the inhibition of NSCLC cell growth and confirmed the
sequence-specific effect. We also found that Cis or Pac up-regulated the expression of PPAR-γ protein, accounting
for the observed sequence-specific synergy. Similarly, experiments performed using a NSCLC xenograft model dem-
onstrated enhanced effectiveness of combined treatment with Cis and PPAR-γ ligands, Tro or pioglitazone. Tumors
from Cis-treated mice also demonstrated enhanced PPAR-γ expression. Together, our data demonstrate a novel
sequence-specific synergy between PPAR-γ ligands and chemotherapeutic agents for lung cancer treatment.
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Introduction
Treatment for lung cancer remains disappointing, with a 5-year survival
rate of only 15% [1]. Induction and maintenance of the differentiated
state has been an important strategy in the search for new cancer
therapeutics. Peroxisome proliferator–activated receptor γ (PPAR-γ), a
ligand-activated nuclear transcription factor, has been shown to exhibit
antiproliferative effects through its ability to promote differentiation in
human breast, prostate, colon, pituitary, and lung tumors [2–6], as well
as through apoptosis [7–12] and cell cycle arrest [10,11,13,14]. Simi-
larly, we have shown that PPAR-γ ligands promote differentiation and
inhibit tumor growth, metastasis, and angiogenesis in non–small cell
lung cancer (NSCLC) [14,15]. Clinical evidence also suggests that
PPAR-γ ligands may be particularly effective against lung cancer. In
a recent study of 87,678 patients at 10 Veterans Affairs medical centers,
Govindarajan et al. [16] found that those receiving thiazolidinediones
(TZDs), the PPAR-γ–activating drugs used by several million patients
for treatment of type 2 diabetes, had a significantly lower risk of lung
cancer. Interestingly, however, there was no significant benefit about
colorectal or prostate cancer.
Abbreviations: 15d-PGJ2, 15-deoxy-Δ
12,14-prostaglandin J2; Cis, cisplatin; NSCLC,
non–small cell lung cancer; Pac, paclitaxel; Pio, pioglitazone; Tro, troglitazone;
TZD, thiazolidinedione
Address all correspondence to: Venkateshwar G. Keshamouni, PhD, Division of Pul-
monary and Critical Care Medicine, Department of Internal Medicine, University of
Michigan Medical Center, 4062 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI
48109-2200. E-mail: vkeshamo@med.umich.edu
1Supported by Flight Attendant Medical Research Institute Grant N005884 (to V.G. K.)
and National Institutes of Health Grants P50 HL60289 (to T.J. S.) and HL070068
(to R.C. R.).
2Current address: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis,
IN 46285.
Received 8 January 2008; Revised 14 March 2008; Accepted 17 March 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.08134
www.neoplasia.com
Volume 10 Number 6 June 2008 pp. 597–603 597
Resistance to standard chemotherapy is a common clinical prob-
lem that creates a continual need for novel strategies to potentiate the
antitumorigenic effects of chemotherapeutic agents. This need in turn
prompted studies to explore the potential adjuvant use of PPAR-γ
ligands with various agents currently in clinical use for cancer. Inves-
tigation of PPAR-γ ligands is further supported by these drugs’ rela-
tively good tolerability and low toxicity profile. In the present study,
we demonstrate that the PPAR-γ ligand troglitazone (Tro) synergis-
tically potentiates cisplatin (Cis)- or paclitaxel (Pac)-induced growth
inhibition of lung cancer cells in vitro. This synergism was observed
only when Tro treatment followed, but not when it preceded, treat-
ment with Cis or Pac. Similarly, the combination of Cis and either Tro
or another PPAR-γ ligand, pioglitazone (Pio), inhibited the growth of
tumor xenografts in vivo significantly more than did any single drug.
Median effect analysis of the interaction between these drugs demon-
strated potent synergy. This sequence-specific synergism may be ex-
plained by our finding that Cis or Pac treatment up-regulates PPAR-γ
expression in lung cancer cells.
Materials and Methods
Cell Culture and Treatment
The A549 and H522 human lung adenocarcinoma cell lines were
obtained from the American Type Culture Collection (Rockville, MD)
and maintained in RPMI 1640 medium with glutamine, supplemen-
ted with 10% fetal bovine serum and antibiotics penicillin and strep-
tomycin. Cells were incubated at 37°C with 5% CO2, and medium
was changed every 48 to 72 hours. For studies of sequence-specific
potentiation, cells were treated in the presence of serum with either
Cis (0, 1, 5, 10, 15, or 20 μM) or Pac (0, 0.25, 1, 10, 50, 100 nM)
for 16 hours followed either by 56 hours of drug-free treatment or by
8 hours of drug-free treatment succeeded by 48 hours of treatment
with Tro at its IC50 of 10 μM. In other studies, cells were pretreated
with Tro (10 μM) for 48 hours followed after 8 hours without drug
by a 16-hour treatment with Cis, Pac, or vehicle at concentrations
similar to those in the preceding experiments. For median effect anal-
ysis, cells were treated with Cis followed by Tro or Tro followed by
Cis according to the described timeline. Each drug was administered
at the same fixed fraction (25%, 50%, 100%, and 200%) of the IC50
(10 μM for each) identified in preliminary experiments. For both sets
of studies, cell growth was analyzed by MTT assay at 72 hours after
initiation of treatment.
Measurement of Cell Growth
Cell growth was assayed using the tetrazolium salt 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
which is cleaved by a mitochondrial dehydrogenase to produce dark
blue formazan crystals [17]. For the assay, MTT was added to the
culture medium, and cells were incubated for an additional 4 hours.
The formazan crystals were then dissolved by the addition of 100 μl
of SDS to each well followed by incubation for a further 5 hours at
37°C. Optical density was measured at 570 nm, and mean values of
duplicate samples were calculated for each well.
Measurement of PPAR-γ Expression
Expression of PPAR-γ was assessed by Western immunoblot anal-
ysis as previously described [14]. Briefly, harvested cells or excised
xenograft tumors were homogenized. Samples containing 20 μg of
total protein were electrophoresed on SDS–polyacrylamide gels and
transferred onto a polyvinyldifluoride membrane by electroblotting.
Membranes were probed with rabbit polyclonal antibodies to total
PPAR-γ (Santa Cruz Biotechnology, Santa Cruz, CA) followed by
horseradish peroxidase–conjugated mouse antirabbit IgG (Pierce,
Rockford, IL).
Median Effect Analysis
We performed median effect analysis as described by Chou and
Talalay [18]. Briefly, the median inhibitory concentration (IC50)
for each drug and for a fixed-ratio combination of the two drugs
was determined. We then calculated the combination index (CI).
For two drugs acting by mechanisms that are not mutually exclusive,
the CI value is defined as:
ðDÞ1
IC50ð Þ1
þ ðDÞ2
IC50ð Þ2
þ ðDÞ1ðDÞ2
IC50ð Þ1 IC50ð Þ2
,
where D1 and D2 are calculated from the IC50 for the combina-
tion and the ratio (P/Q) of the two drugs by the equations: D1 =
(IC50)comb × P / (P + Q) and D2 = (IC50)comb × Q / (P + Q). The
third (interaction) term is absent when the drug actions are mutually
exclusive. For each drug combination in our study we used Calcusyn
software (Biosoft, Ferguson, MO) to calculate the CI for 4 concen-
trations (1:1 ratio) of the two drugs and averaged the CIs. A CI of
1 indicates additive effects, whereas a CI < 1 indicates synergy.
Xenografts in SCID Mice and Analysis of Tumor Growth
Six-week-old C.B-17 SCID mice (Taconic Farms, Germantown,
NY) were subcutaneously injected with A549 cells on either side of
the dorsal flank. Beginning after tumor size reached approximately
150 mm3, six mice per group were treated with Cis (3 mg/kg) weekly
by intraperitoneal injection and, beginning 4 days later, received Tro
(400 mg/kg), Pio (100 mg/kg), or vehicle once daily by oral gavage.
Tro and Pio were formulated by suspending the drug in an aqueous
solution of 2% carboxymethylcellulose and 0.2% Tween 20 and then
sonicating for 5 minutes. Other mice received vehicle intraperitoneal
injections in combination with either Tro or vehicle by oral gavage.
Tumor size was measured weekly for 10 weeks, and tumor volume
was calculated by averaging the largest and smallest radii and multiply-
ing the cube of the result by π. After 10 weeks of treatment, mice were
killed and PPAR-γ expression in tumors was measured by Western
immunoblot analysis. All experiments were approved by the University
of Michigan Committee on Use and Care of Animals.
Statistical Analysis
All data are expressed as means ± SEM and are analyzed using the
Prism 5.0 statistical program (GraphPad Software, San Diego, CA).
Groups were compared using one-sided analysis of variance or one-
sided Student’s t test as applicable. P < .05 was considered significant.
Results
Tro Potentiates Cis- or Pac-Induced Growth Inhibition in a
Sequence-Specific Manner
To assess the efficacy of combining Tro with either of the chemo-
therapeutic agents Cis or Pac to inhibit NSCLC cell growth, A549
cells were treated with various concentrations of Tro, Cis or Pac in four
different combinations as described in the Materials and Methods sec-
tion and Figure 1A. After 72 hours, cell growth was assessed by MTT
assay. We observed that A549 cells treated with Cis or Pac and fol-
lowed by Tro demonstrated maximum growth inhibition compared
with individual drug alone (Figure 1, B and C ). Interestingly, A549
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cells that were first treated with Tro and then followed by Cis or Pac
were not significantly different from the individual drug treatments,
demonstrating a sequence-specific effect. Furthermore, we observed
a similar sequence-specific effect on cell growth inhibition when Cis
treatment was followed by Tro in another NSCLC-derived cell line,
H522 (Figure 2A). This demonstrates that the effects we observed
in A549 cells were not cell line specific.
Median Effect Analysis Reveals Sequence-Specific Synergistic
Interaction between Tro and Cis
We then assessed the interaction between Cis and Tro by median
effect analysis. For these studies, Tro and Cis were each administered
in a 1:1 ratio at four fractions of their IC50 concentrations (10 μM
for each). The respective dose-effect curves are displayed in Figure 3,
A and D, and are linearized by log-log transformation in Figure 3, B
and E. The straightness of the lines demonstrates that these data are
suitable for median effect analysis, whereas the parallelism of the lines
in Figure 3B demonstrates that growth inhibition by Cis and by Tro
after treatment are mutually exclusive. The fraction-effect versus CI
plots (Figure 3, C and F ) indicate the nature of the interaction be-
tween the drugs being tested. The CI, for the combination with Cis
treatment followed by Tro, is consistently below 1 (Figure 3C ), with
Figure 1. Sequence-specific potentiation of cisplatin- or paclitaxel-
induced growth inhibition by troglitazone (Tro) in A549 cells. (A)
Timeline of in vitro experiments: i, in studies of Tro after treat-
ment, cells were treated with cisplatin (Cis) or paclitaxel (Pac) for
16 hours followed by an 8-hour drug-free washout and Tro for
48 hours; ii, in studies of Tro before treatment, cells were treated
with Tro for 48 hours followed by an 8-hour drug-free washout
and Cis or Pac for 16 hours; iii, in studies of Tro as a single agent,
Tro was administered for 48 hours followed by 24 hours without
drug; iv, in studies of Cis or Pac as single agents, they were ad-
ministered for 16 hours followed by 56 hours without drug. In
single-agent studies, cells were treated with Tro at concentrations
of 0, 1, 5, 10, 15, or 20 μM, Cis at concentrations of 0, 1, 5, 10, 15,
or 20 μM, or Pac at concentrations of 0, 0.25, 1, 10, 50, or 100 nM.
In combination studies, cells were treated with 10 μM Tro before
or after various concentrations of Cis and Pac as indicated. (B)
A549 cell growth kinetics in various combinations of Tro and Cis.
(C) A549 cell growth kinetics in various combinations of Tro and
Pac. Results shown are averages of six replicate experiments.
Figure 2. Sequence-specific synergistic potentiation of cisplatin
(Cis)-induced growth inhibition by troglitazone (Tro) in H522 cells.
H522 cells were treated with Cis and/or Tro according to the pro-
tocol previously described for A549 cells. (A) Growth curves for
treatment with Cis alone, Tro alone, Cis followed by Tro, and Tro
followed by Cis. (B) CIs, derived from median effect analysis, for
each drug concentration and order of administration. CI values < 1
indicate synergy and values > 1 indicate partial antagonism.
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an average of 0.59. The average CI of <1 demonstrates that the ef-
fects of the two drugs are synergistic. On the other hand, for the
combination that has Tro treatment preceding the Cis treatment,
the CI is consistently greater than 1 (Figure 3F ), with an average
of 3.62. The CI > 1 indicates that the interaction is partially antag-
onistic. Median effect analysis in H522 cells also demonstrated sim-
ilar synergistic interaction when Cis is followed by Tro (average CI of
0.30) and not vice versa (average CI of 3.33; Figure 2B).
Cis or Pac Induces PPAR-γ Expression
In preliminary studies investigating the regulation of PPAR-γ ex-
pression in A549 cells, we found that inducing growth inhibition by
serum deprivation up-regulated PPAR-γ expression (Figure 4). We
therefore investigated the effect of inhibiting growth by exposure
to Cis or Pac. We found that exposure to either Cis or Pac for 16 hours
significantly up-regulated PPAR-γ expression as assessed by West-
ern immunoblot analysis, with the extent of the increase being
dose-dependent (Figure 4).
Tro or Pio Treatment Enhances the Effect of Cis on Growth of
A549 Tumor Xenografts in SCID Mice
To determine whether the enhanced tumor suppression we observed
with Tro in vitro could also be observed in vivo, we used a xenograft
model in which NSCLC-derived A549 cells are injected into either
side of the dorsal flank of SCID mice. After the tumors had reached
a mean volume of approximately 150 mm3, mice were divided into six
different groups. As summarized in Figure 5A, treatment with Cis
(3 mg/kg) or vehicle once weekly by intraperitoneal injection was be-
gun at this time for 3 groups of mice. Four days later, each of the 3 Cis
treatment groups received either Tro (400 mg/kg), Pio (100 mg/kg), or
vehicle daily by oral gavage. The remaining 3 groups were either un-
treated, or received Tro or Pio alone as described. All treatments were
continued for 10 weeks, and tumor volumes were monitored by
weekly measurements (Figure 5B). All three drugs as single agents
significantly inhibited the growth of A549 xenografts. Consistent
with our in vitro observations, combination treatments of either Cis
and Tro or Cis and Pio were significantly more effective in inhibiting
A549 xenografts than either drug alone.
Figure 3.Median effect analysis reveals synergistic interaction when cisplatin (Cis) treatment is followed by troglitazone (Tro) but partial
antagonism when Tro treatment precedes cisplatin. After determining the IC50 for each drug, Tro and Cis were administered in a fixed
ratio with two concentrations below and one concentration above their IC50 concentrations (10 μM), in a total of four different ratios
(2.5:2.5, 5:5, 10:10, and 20:20 in μM). Cell proliferation was assessed by MTT assay after 72 hours. Results for Tro after treatment are
displayed in panels (A), (B), and (C) and for Tro before treatment in panels (D), (E), and (F). Dose-effect curves for Cis as a function of Tro
concentration are displayed in panels (A) and (D) and after log-log transformation in panels (B) and (E); panels (C) and (F) show the Fa-CI
curves calculated using the median effect equation. Values < 1 indicate synergy and values > 1 indicate partial antagonism.
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Cis Up-regulates PPAR-γ Expression in Xenografts
Similar to our in vitro observations, we determined whether Cis up-
regulated PPAR-γ expression in xenografts. For this, we assessed
PPAR-γ expression in the tumor tissue lysates from A549 xenografts
after indicated treatment regimens by Western immunoblot analysis.
As shown in Figure 6, we observed significant up-regulation of PPAR-γ
expression in the tumors from mice that received Cis treatment.
Densitometric scans (Figure 6B) confirmed the significance of up-
regulation both by Cis alone and by the addition of Cis to Tro treat-
ment. These observations further support the hypothesis that induc-
tion of PPAR-γ expression by chemotherapeutic drugs is important for
potentiating the effect of subsequent treatment with PPAR-γ ligands.
Discussion
In this study, we demonstrate synergy between PPAR-γ ligands
and two cancer chemotherapeutic agents of different classes, one
platinum-based and the other a taxane. These effects were seen both
in vitro, as inhibition of growth in two NSCLC-derived cell lines,
and in vivo as inhibition of tumor growth in a xenograft model. Me-
dian effect analysis of varying doses of the drugs demonstrated true
synergy rather than a mere additive effect. Perhaps the most striking
aspect of our findings is that synergy was specific to the sequence
in which the agents were administered, specifically, Cis followed by
Tro and not vice versa. These results may be attributed to the fact
that Cis or Pac treatment results in the up-regulation of PPAR-γ ex-
pression, which is expressed to varying degrees in both normal and
tumor epithelia [19]. We observed a similar up-regulation of PPAR-γ
expression during serum-deprivation–induced growth inhibition.
These data suggest that during the observed synergistic interaction,
the growth-inhibiting effect of chemotherapeutic agents potentiate
the differentiation-inducing effects of PPAR-γ ligands by increas-
ing the availability of their receptor. Consistently, we also observed
up-regulation of PPAR-γ expression in all the Cis-treated tumor groups
in the xenograft model. In addition, two different PPAR-γ ligands were
equally effective in enhancing the effects of Cis in inhibiting tumor
growth. This supports our conclusion that the observed synergy re-
flects activation of the increased levels of PPAR-γ. By contrast, a par-
tial antagonistic effect was observed when the cells were treated with
PPAR-γ ligand before the chemotherapeutic agent. This may be be-
cause PPAR-γ ligands inhibit cell proliferation, and cytotoxic agents
such as Cis are less effective against nondividing cells.
Two recent studies have also reported apparently synergistic effects
against NSCLC-derived cell lines and mouse xenografts after combi-
nation treatment with PPAR-γ ligands and chemotherapeutic agents.
Girnun et al. [20] assessed the combination of the TZD rosiglitazone
and the platinum-based drug carboplatin, whereas Fulzele et al. [21]
studied the natural PPAR-γ ligand 15-deoxy-Δ12,14-prostaglandin J2
(15d-PGJ2) and the taxane docetaxel. Furthermore, Copland et al.
[22] found that the novel PPAR-γ ligand RS5444 enhanced the activ-
ity of Pac against anaplastic thyroid carcinoma in vitro and in a xeno-
graft model. However, this group found only additive antiproliferative
effects, whereas Girnun et al. [20] did not statistically evaluate whether
the enhanced effectiveness they observed was truly synergistic. Addi-
tionally, in all three studies, the drugs were administered concurrently,
as opposed to the sequential treatment we followed. This allowed us to
demonstrate that the effects of Tro and Cis are mutually exclusive.
Girnun et al. [20] attributed the synergy they observed to rosigli-
tazone-induced inhibition of metallothionein expression. Metallo-
thioneins are proteins that bind heavy metals, including platinum,
and thus cause sequestration of platinum-based drugs in cancer cells.
This effect on metallothionein expression may also contribute to the
Figure 4. Serum deprivation or exposure to either cisplatin (Cis) or
paclitaxel (Pac) induces PPAR-γ expression. A549 cells were either
cultured in serum-free medium for 72 hours (first column) or were
exposed in the presence of serum to Cis (1 or 5 μM), Pac (1 or
5 nM), or vehicle for 16 hours followed by 56 hours in drug-free
medium with serum. At the end of 72 hours, PPAR-γ was as-
sessed by Western immunoblot analysis. β-Actin expression is
displayed as a loading control.
Figure 5. Combined treatment with cisplatin (Cis) and troglitazone
(Tro) or pioglitazone (Pio) is more effective than any drug alone
against tumor growth in a xenograft model. A549 cells were inoc-
ulated subcutaneously into the flanks of SCID mice. (A) Experi-
mental design: After the tumor size had reached approximately
150 mm3, mice (six mice/group) were injected weekly with
3-mg/kg Cis and, beginning 4 days later, were treated daily with
Tro (400 mg/kg), Pio (100 mg/kg), or vehicle by oral gavage. In
other studies, mice were treated with Tro, Pio, or vehicle as de-
scribed but received vehicle (for Cis) by intraperitoneal injection.
(B) Tumor size was measured weekly for 10 weeks, beginning at
the initiation of treatment, and tumor volume was calculated by
averaging the largest and smallest radii and multiplying the cube
of the result by π. *P < .05, **P < .01, and ***P < .001 compared
with Ctrl at week 10 by analysis of variance.
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synergy we observed. However, it accounts neither for our observation
of a sequence-specific effect nor for the effect on activity of the non-
platinum drug Pac. Nevertheless, it is entirely possible and perhaps
likely that more than one mechanism is operating when PPAR-γ li-
gands and chemotherapeutic drugs are administered simultaneously.
In addition to enhancing the efficacy of general chemotherapeutics
such as platinum-based drugs and taxanes, PPAR-γ ligands are also
implicated in enhancing the efficacy of several targeted therapeutics.
Lee et al. [23] showed that the PPAR-γ ligand rosiglitazone facilitated
the antiproliferative effects of gefitinib, an inhibitor of the epidermal
growth factor receptor tyrosine kinase. Similarly, Han and Roman
[24] reported that the inhibitory effect of rosiglitazone on the growth
of NSCLC-derived cell lines was facilitated by the chemotherapeutic
agent rapamycin. Increased growth inhibition and apoptosis of A549
cells has also been demonstrated after combined treatment with
MK886, an inhibitor of 5-lipoxygenase activator protein, the cy-
clooxygenase inhibitor indomethacin, and 15d-PGJ2 [25]. Further-
more, a novel PPAR-α/γ ligand has been reported to synergistically
enhance the antiproliferative and proapoptotic effects of imatinib
against chronic myeloid leukemia cell lines [26].
PPAR-γ/PPAR-γ ligands exert their antitumor effects on NSCLC
cells directly as well by a variety of mechanisms. One effect involves
suppression of the tumorigenic mediator prostaglandin E2. Studies have
shown that up-regulation of PPAR-γ reduces synthesis of prostaglan-
din E2 by down-regulating cyclooxygenase-2 expression [27] while
PPAR-γ ligands increase catabolism of the molecule by up-regulating
15-hydroxyprostaglandin dehydrogenase [28]. Treatment with PPAR-γ
ligands also leads to increased expression of the growth arrest and DNA
damage-inducible 153 (GADD153) gene, which is believed to mediate
apoptosis [29]. Another mechanism by which PPAR-γ ligands may
exert antitumor effects is through up-regulation of E-cadherin, which is
thought to promote differentiation of NSCLC cells [30]. Furthermore,
we have shown that PPAR-γ activation inhibits angiogenesis by block-
ing production of chemokines of the ELR+ CXC family [15] and pro-
duces cell cycle arrest by down-regulating cyclins D and E [14]. We also
observed sustained up-regulation of extracellular regulated kinase 1/2,
which may initiate the pathway leading to differentiation.
In the context of the present study, the possibility that PPAR-γ
ligands may be more effective against NSCLC than many other can-
cers is intriguing. As previously mentioned, a large epidemiological
study has found that TZD use reduces the risk of lung cancer but
not of colorectal or prostate cancer [16]. Lack of any effect of TZD
use on risk of colon and prostate cancer, as well as breast cancer, has
similarly been found in an even larger epidemiological study [31].
Conversely, the smaller study of Ramos-Nino et al. [32] found an
increased overall cancer risk among TZD users. This study did not
identify the risks for individual types of cancer, so possible implications
for NSCLC are difficult to assess.
In conclusion, our results demonstrate that PPAR-γ ligands act
synergistically with both the platinum-based chemotherapeutic agent
Cis and the taxane Pac to inhibit the growth of NSCLC cells both
in vitro and in vivo. Strikingly, this synergism is dependent on the se-
quence in which these drugs are administered, which presumably re-
flects the increased PPAR-γ expression observed after treatment with
the chemotherapeutic agents. This finding raises the possibility that
PPAR-γ ligands may be clinically useful not only in combination
with Cis and Pac but also as salvage therapy after prior cytotoxic ther-
apy has failed.
Figure 6. Cisplatin (Cis) up-regulates PPAR-γ expression in tumor xenografts. A549 cells were inoculated subcutaneously into the flanks
of SCID mice as previously described. After 10 weeks of treatment with vehicle (C1–5), cisplatin (Cis1–5), troglitazone (Tro1–5), or Cis +
Tro, mice were killed, and tumors were resected and assayed for PPAR-γ expression by Western immunoblot analysis. (A) Blots of
PPAR-γ and the β-actin loading control are shown for each mouse. (B) Densitometric scans showing mean PPAR-γ expression, normal-
ized to β-actin, for each condition.
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